Matching articles for "CYP2C9"
Issue 1332 · February 22, 2010
Vigabatrin (Sabril) for Epilepsy

The FDA has approved vigabatrin (vye gá ba trin; Sabril – Lundbeck) for oral use as add-on therapy for complex partial seizures in adults who are refractory to several antiepileptic drugs and as monotherapy…

Med Lett Drugs Ther. 2010 Feb 22; 52(1332):14-6
The FDA has approved vigabatrin (vye gá ba trin; Sabril – Lundbeck) for oral use as add-on therapy for complex partial seizures in adults who are refractory to several antiepileptic drugs and as monotherapy for infantile spasms. Vigabatrin has been available in other countries for many years. Because of its potential for retinal toxicity, it will be available in the US only through a restricted distribution program called SHARE (Support, Help and Resources for Epilepsy). Prescribers and pharmacists distributing the drug must register, and patients must undergo visual field testing.
Issue 88 · December 1, 2009
Antifungal Drugs

The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online…

Treat Guidel Med Lett. 2009 Dec; 7(88):95-102
The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online from the Infectious Diseases Society of America ( www.idsociety.org ).
Issue 85 · September 1, 2009
Drugs for Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is either Crohn's disease or ulcerative colitis. Drug selection is guided by disease type (Crohn's versus ulcerative colitis), severity and location and whether the goal is…

Treat Guidel Med Lett. 2009 Sep; 7(85):65-74
Inflammatory bowel disease (IBD) is either Crohn's disease or ulcerative colitis. Drug selection is guided by disease type (Crohn's versus ulcerative colitis), severity and location and whether the goal is induction or maintenance of remission. Table 1 on page 66 lists the drugs used to treat IBD with their formulations and cost. Table 2 on page 68 lists the drugs of choice and their doses for different indications. Table 3 on page 71 lists the drugs' adverse effects and recommendations for monitoring. More detailed guidelines are available from the American College of Gastroenterology.
Issue 1308 · March 23, 2009
Dexlansoprazole (Kapidex) for GERD and Erosive Esophagitis

The FDA has approved the proton-pump inhibitor (PPI) dexlansoprazole ( Kapidex - Takeda), a delayed release formulation of the R-enantiomer of lansoprazole ( Prevacid - Takeda), for treating and maintaining…

Med Lett Drugs Ther. 2009 Mar 23; 51(1308):21-2
The FDA has approved the proton-pump inhibitor (PPI) dexlansoprazole ( Kapidex - Takeda), a delayed release formulation of the R-enantiomer of lansoprazole ( Prevacid - Takeda), for treating and maintaining healing of erosive esophagitis and for treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD).
Issue 1288 · June 16, 2008
Etravirine (Intelence) for HIV Infection

Etravirine ( Intelence - Tibotec), a new non-nucleoside reverse transcriptase inhibitor (NNRTI), has received fast-track FDA approval for use in combination therapy in treatment-experienced adults who have…

Med Lett Drugs Ther. 2008 Jun 16; 50(1288):47-8
Etravirine ( Intelence - Tibotec), a new non-nucleoside reverse transcriptase inhibitor (NNRTI), has received fast-track FDA approval for use in combination therapy in treatment-experienced adults who have HIV-1 infection resistant to an NNRTI and other antiretroviral agents.
Issue 1288 · June 16, 2008 Free
Addendum: Warfarin-Acetaminophen Interaction

A reader expressed disappointment that our recent listing of “Some Warfarin Drug Interactions” 1 did not include acetaminophen. Perhaps it should have. Acetaminophen can increase the anticoagulant effect…

Med Lett Drugs Ther. 2008 Jun 16; 50(1288):45
A reader expressed disappointment that our recent listing of “Some Warfarin Drug Interactions” 1 did not include acetaminophen. Perhaps it should have. Acetaminophen can increase the anticoagulant effect of warfarin, particularly with continued use, but it does so inconsistently. The mechanism of this interaction has not been established, but may be related to an acetaminophen metabolite inhibiting vitamin K-epoxide reductase, the target for warfarin’s anticoagulant effect. 2 Patient susceptibility varies, possibly on a genetic basis; occasional use of acetaminophen generally has little or no effect on the international normalized ratio (INR) in patients on chronic warfarin therapy, but in some, even a few grams of the drug may cause a dramatic increase in INR. One study in healthy subjects found no effect of acetaminophen 4 g per day for 2 weeks, while another study in patients with the same acetaminophen dose for the same period of time found a moderate increase in INR. 3,4 It might be prudent to monitor INR in patients on chronic warfarin therapy more closely than usual when they take more than 2 g per day of acetaminophen for more than a few days. 1. Pharmacogenetic-based dosing of warfarin. Med Lett Drugs Ther 2008; 50:39. 2. HH Thijssen et al. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost 2004; 92:797. 3. D Kwan et al. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39:68. 4. I Mahe et al. Paracetamol: A haemorrhagic risk factor in patients on warfarin. Br J Clin Pharmacol 2005; 59:371. Download U.S. English
Issue 1286 · May 19, 2008
Pharmacogenetic-Based Dosing of Warfarin

Warfarin sodium ( Coumadin , and others) and other coumarin anticoagulants prevent thrombosis, but patient response is highly variable and overanticoagulation can lead to hemorrhage. Genotyping patients for…

Med Lett Drugs Ther. 2008 May 19; 50(1286):39-40
Warfarin sodium ( Coumadin , and others) and other coumarin anticoagulants prevent thrombosis, but patient response is highly variable and overanticoagulation can lead to hemorrhage. Genotyping patients for single nucleotide polymorphisms (SNPs) that affect coumarin metabolism and sensitivity may help clinicians estimate the therapeutic warfarin dose. The FDA has added a note to warfarin labeling recommending lowrange doses for patients with such genetic variations. Commercial tests for these variants are now available and cost about $500 per test.